


Corrigendum

Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Stefanie Howaldt, MD,* Eugeni Domènech, MD, PhD,[†] Nicholas Martinez, MD,[‡] Carsten Schmidt, MD,[§] and Bernd Bokemeyer, MD[¶]; on behalf of the AEGIS Trialists

From the *Research Institute for IBD–HaFCEd e.K., Hamburg, Germany

[†]Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Madrid, Spain

[‡]Gastroenterology Research of America, San Antonio, Texas, USA

[§]Department of Gastroenterology, Hepatology, Endocrinology, Diabetology, and Infectious Diseases, Klinikum Fulda, Fulda, Germany

[¶]Gastroenterology Practice Minden and University Hospital Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine I, Kiel, Germany

Address correspondence to: Stefanie Howaldt, MD, Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen, Christoph-Probst-Weg 4, 20251 Hamburg, Germany (howaldt@hafced.de).

In the article titled “Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial”, the legends for Figures 3 and 4 were incorrect.

The incorrect legends read as follows:

“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population, observed patients). *P* values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”

“Figure 4. Patients achieving ≥ 1 and ≥ 2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). *P* values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”

The legends should read as follows:

“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population). *P* values shown for least-squares mean change from baseline, difference between groups.”

“Figure 4. Patients achieving ≥ 1 and ≥ 2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). *P* values shown for risk difference between groups.”

These errors have been corrected online and in print.